Takeda Pharmaceutical Company Limited Contingent Liabilities Recognised In Business Combination
Takeda Pharmaceutical Company Limited (TAK) had Contingent Liabilities Recognised In Business Combination of JPY 4.36 billion as of 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Notes
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination · last filed 2025-06-25
- 2025-03-31: Contingent Liabilities Recognised In Business Combination 4.36B JPY.
- 2024-03-31: Contingent Liabilities Recognised In Business Combination 7.77B JPY.
- 2023-03-31: Contingent Liabilities Recognised In Business Combination 8.14B JPY.
- 2022-03-31: Contingent Liabilities Recognised In Business Combination 5.84B JPY.
| Period end | Contingent Liabilities Recognised In Business Combination | Contingent Liabilities Recognised In Business Combination as first filed |
|---|---|---|
| 2025-03-31 | 4.36B JPY 20-F · filed 2025-06-25 | |
| 2024-03-31 | 7.77B JPY 20-F · filed 2025-06-25 | |
| 2023-03-31 | 8.14B JPY 20-F · filed 2025-06-25 | |
| 2022-03-31 | 5.84B JPY 20-F · filed 2024-06-26 | |
| 2021-03-31 | 27.77B JPY 20-F · filed 2023-06-28 | |
| 2020-03-31 | 41.66B JPY 20-F · filed 2022-06-29 | |
| 2019-03-31 | 67.29B JPY 20-F · filed 2021-06-29 | 71.06B JPY 20-F · filed 2019-06-27 |
| 2018-03-31 | 30.57B JPY 20-F · filed 2020-06-24 | |
| 2017-03-31 | 28.98B JPY 20-F · filed 2019-06-27 |